Alembic Ltd
ALEMBICLTDAlembic Ltd
ALEMBICLTDPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
11.11 | 1.58 | 1.79% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.49 | 6.67 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alembic Limited is engaged in the business of pharmaceuticals, real estate and power assets. The Company's segments include API and Real Estate.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 162.76 | 178.13 | 162.32 | 153.26 | 167.33 | 83.79 | 167.40 | 191.50 | 212.26 | 263.88 | ||||||||||
Raw Materials | 37.64 | 50.97 | 39.86 | 45.21 | 24.59 | 11.77 | 8.53 | 6.92 | 8.62 | 116.25 | ||||||||||
Power & Fuel Cost | 13.26 | 5.46 | 1.11 | 2.34 | 0.91 | 0.42 | 0.15 | 2.02 | 1.18 | |||||||||||
Employee Cost | 27.01 | 28.64 | 19.64 | 20.52 | 20.79 | 22.60 | 21.47 | 24.04 | 23.03 | |||||||||||
Selling & Administrative Expenses | 7.62 | 7.38 | 7.13 | 7.26 | 9.17 | 7.56 | 9.82 | 10.81 | 14.04 | |||||||||||
Operating & Other expenses | 45.64 | 53.80 | 46.45 | 30.41 | 15.19 | 20.10 | 24.33 | 53.73 | 53.76 | |||||||||||
EBITDA | 31.59 | 31.88 | 48.13 | 47.52 | 96.68 | 21.34 | 103.10 | 93.98 | 111.63 | 147.63 | ||||||||||
Depreciation/Amortization | 6.14 | 5.09 | 3.78 | 2.63 | 3.23 | 3.94 | 4.86 | 6.72 | 7.84 | 9.32 | ||||||||||
PBIT | 25.45 | 26.79 | 44.35 | 44.89 | 93.45 | 17.40 | 98.24 | 87.26 | 103.79 | 138.31 | ||||||||||
Interest & Other Items | 0.12 | 0.16 | 0.17 | 0.22 | 0.29 | 0.36 | 0.39 | 0.47 | 1.11 | 2.01 | ||||||||||
PBT | 25.33 | 26.63 | 44.18 | 44.67 | 93.16 | 17.04 | 97.85 | 86.79 | 102.68 | 136.30 | ||||||||||
Taxes & Other Items | -209.18 | -118.75 | -118.81 | -168.43 | -235.95 | -325.80 | -124.20 | -103.85 | -165.93 | -174.09 | ||||||||||
Net Income | 234.51 | 145.38 | 162.99 | 213.10 | 329.11 | 342.84 | 222.05 | 190.64 | 268.61 | 310.39 | ||||||||||
EPS | 7.15 | 4.43 | 4.97 | 6.62 | 11.50 | 13.35 | 8.65 | 7.42 | 10.46 | 12.09 | ||||||||||
DPS | 0.12 | 0.16 | 0.16 | 0.16 | 0.60 | 0.20 | 1.80 | 2.20 | 2.40 | 2.40 | ||||||||||
Payout ratio | 0.02 | 0.04 | 0.03 | 0.02 | 0.05 | 0.01 | 0.21 | 0.30 | 0.23 | 0.20 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Alembic Ltd | 12.84 | 1.58 | 1.79% |
Sun Pharmaceutical Industries Ltd | 46.13 | 6.58 | 0.73% |
Cipla Ltd | 29.21 | 4.49 | 0.87% |
Mankind Pharma Ltd | 62.91 | 12.57 | — |
Price Comparison
Compare ALEMBICLTD with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Dividend Yield
Current dividend yield is 1.79%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹17.87 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 5, 2024
Dividend/Share
₹2.40
Ex DateEx Date
Aug 5, 2024
Cash Dividend
Ex DateEx DateAug 3, 2023
Dividend/Share
₹2.20
Ex DateEx Date
Aug 3, 2023
Cash Dividend
Ex DateEx DateSep 12, 2022
Dividend/Share
₹1.80
Ex DateEx Date
Sep 12, 2022
Cash Dividend
Ex DateEx DateJul 29, 2021
Dividend/Share
₹0.20
Ex DateEx Date
Jul 29, 2021
Cash Dividend
Ex DateEx DateJul 29, 2020
Dividend/Share
₹0.60
Ex DateEx Date
Jul 29, 2020
Net profit of Alembic rose 33.46% to Rs 121.02 crore in the quarter ended September 2024 as against Rs 90.68 crore during the previous quarter ended September 2023. Sales rose 63.91% to Rs 52.91 crore in the quarter ended September 2024 as against Rs 32.28 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales52.9132.28 64 OPM %37.0131.44 - PBDT84.5157.89 46 PBT81.8356.03 46 NP121.0290.68 33 Powered by Capital Market - Live
Alembic will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
Net profit of Alembic rose 25.78% to Rs 55.82 crore in the quarter ended June 2024 as against Rs 44.38 crore during the previous quarter ended June 2023. Sales rose 37.84% to Rs 50.78 crore in the quarter ended June 2024 as against Rs 36.84 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales50.7836.84 38 OPM %40.1729.53 - PBDT21.8713.38 63 PBT19.3711.55 68 NP55.8244.38 26 Powered by Capital Market - Live
Alembic’s shares dip amidst US market product recall
Housing & Urban Development Corporation Ltd leads gainers in ‘A’ group
Alembic Ltd leads gainers in ‘A’ group
This multibagger stock sets record date for 90% dividend
Surya Roshni Ltd leads gainers in ‘A’ group
Alembic Ltd leads gainers in ‘A’ group
Volumes spurt at Alembic Ltd counter
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 6.73%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.07% to 0.06%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 4.74%, vs industry avg of 15.28%